Bristol-Myers Squibb (NYSE:BMY) Stake Lifted by Centaurus Financial Inc.

Centaurus Financial Inc. increased its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 11.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,175 shares of the biopharmaceutical company’s stock after buying an additional 1,256 shares during the quarter. Centaurus Financial Inc.’s holdings in Bristol-Myers Squibb were worth $689,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Pinney & Scofield Inc. bought a new position in shares of Bristol-Myers Squibb in the fourth quarter worth $25,000. Park Square Financial Group LLC bought a new position in shares of Bristol-Myers Squibb in the fourth quarter worth $26,000. Fairway Wealth LLC bought a new position in shares of Bristol-Myers Squibb in the fourth quarter worth $28,000. Transce3nd LLC bought a new position in shares of Bristol-Myers Squibb in the fourth quarter worth $28,000. Finally, Comprehensive Financial Planning Inc. PA bought a new position in shares of Bristol-Myers Squibb in the fourth quarter worth $34,000. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Stock Performance

Shares of BMY opened at $47.80 on Friday. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33. The company has a 50-day moving average of $50.71 and a two-hundred day moving average of $55.46. The stock has a market cap of $97.27 billion, a price-to-earnings ratio of -10.81, a PEG ratio of 2.07 and a beta of 0.39. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company had revenue of $11.20 billion during the quarter, compared to analysts’ expectations of $10.77 billion. During the same period last year, the company posted ($4.40) earnings per share. The business’s revenue for the quarter was down 5.6% on a year-over-year basis. On average, equities research analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.19%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 92.88%.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Piper Sandler assumed coverage on Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $65.00 price target for the company. Argus raised Bristol-Myers Squibb to a “hold” rating in a research note on Friday, April 25th. Wells Fargo & Company upped their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a report on Friday, February 7th. UBS Group decreased their target price on Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a research note on Friday, April 11th. Finally, Jefferies Financial Group decreased their target price on Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a research note on Wednesday, April 23rd. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, Bristol-Myers Squibb currently has an average rating of “Hold” and an average price target of $58.00.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Samit Hirawat purchased 4,250 shares of Bristol-Myers Squibb stock in a transaction dated Friday, April 25th. The stock was acquired at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the transaction, the executive vice president now directly owns 83,513 shares of the company’s stock, valued at $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.